DE60121804D1 - Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin - Google Patents
Pharmazeutische zusammensetzung eines biguanin (metformin) und argininInfo
- Publication number
- DE60121804D1 DE60121804D1 DE60121804T DE60121804T DE60121804D1 DE 60121804 D1 DE60121804 D1 DE 60121804D1 DE 60121804 T DE60121804 T DE 60121804T DE 60121804 T DE60121804 T DE 60121804T DE 60121804 D1 DE60121804 D1 DE 60121804D1
- Authority
- DE
- Germany
- Prior art keywords
- biguanine
- metformin
- arginine
- pharmaceutical composition
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000004475 Arginine Substances 0.000 title 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 title 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title 1
- 229960003105 metformin Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0017332A FR2818906B1 (fr) | 2000-12-29 | 2000-12-29 | Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine |
| FR0017332 | 2000-12-29 | ||
| PCT/FR2001/004235 WO2002053090A2 (fr) | 2000-12-29 | 2001-12-31 | Association medicamenteuse d'une biguanine (metformine) et d'arginine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60121804D1 true DE60121804D1 (de) | 2006-09-07 |
| DE60121804T2 DE60121804T2 (de) | 2007-08-23 |
Family
ID=8858430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60121804T Expired - Lifetime DE60121804T2 (de) | 2000-12-29 | 2001-12-31 | Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7265156B2 (de) |
| EP (1) | EP1349578B1 (de) |
| JP (1) | JP4477301B2 (de) |
| AT (1) | ATE333901T1 (de) |
| CA (1) | CA2435484A1 (de) |
| CY (1) | CY1105736T1 (de) |
| DE (1) | DE60121804T2 (de) |
| DK (1) | DK1349578T3 (de) |
| ES (1) | ES2271103T3 (de) |
| FR (1) | FR2818906B1 (de) |
| NZ (1) | NZ527206A (de) |
| PT (1) | PT1349578E (de) |
| RU (1) | RU2003123491A (de) |
| WO (1) | WO2002053090A2 (de) |
| ZA (1) | ZA200207761B (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| KR101541791B1 (ko) | 2006-05-04 | 2015-08-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 다형태 |
| EP1852108A1 (de) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Zusammensetzungen von DPP-IV-Inhibitoren |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| CA2776296C (en) | 2009-10-02 | 2017-11-07 | Boehringer Ingelheim International Gmbh | Therapeutic uses of pharmaceutical compositions |
| WO2011051974A1 (en) * | 2009-10-29 | 2011-05-05 | Nutracryst Therapeutics Private Limited | Metformin and a-amino acids |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| US20120178813A1 (en) * | 2011-01-12 | 2012-07-12 | Thetis Pharmaceuticals Llc | Lipid-lowering antidiabetic agent |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| EP4151218A1 (de) | 2012-05-14 | 2023-03-22 | Boehringer Ingelheim International GmbH | Linagliptin, ein xanthinderivat als dpp-4-inhibitor zur verwendung bei der behandlung von sirs und/oder sepsis |
| CN105277705A (zh) * | 2014-07-24 | 2016-01-27 | 江苏维赛科技生物发展有限公司 | 一种检测双胍类药物残留的试剂盒的制备及其检测方法 |
| WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2037002A1 (en) | 1969-04-30 | 1970-12-31 | Roques Bernard | N-substd biguanide pamoic acid salts prepn |
| FR2696740B1 (fr) * | 1992-10-13 | 1994-12-30 | Dospharma Sa | Dérivés prodrogués de la diméthylbiguanide et applications comme médicaments. |
| ES2216335T3 (es) * | 1997-12-08 | 2004-10-16 | Bristol-Myers Squibb Company | Nuevas sales de metformina y procedimiento. |
| EP1063973B1 (de) * | 1998-03-19 | 2016-11-16 | Bristol-Myers Squibb Company | Zweiphasiges kontrolliertes verabreichungssystem für hochlösliche arzneimittel und verwandtes verfahren |
| AU3536299A (en) * | 1998-04-29 | 1999-11-16 | Sumitomo Pharmaceuticals Company, Limited | Oral formulation comprising biguanide and an organic acid |
| FR2796551B1 (fr) | 1999-07-23 | 2003-07-25 | Lipha | Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant |
| AU2001213150A1 (en) | 2000-08-03 | 2002-02-18 | Olga Evgenievna Kolesova | Composition of metformin with succinic acid or salts thereof and method for treating diabetes |
-
2000
- 2000-12-29 FR FR0017332A patent/FR2818906B1/fr not_active Expired - Fee Related
-
2001
- 2001-12-31 RU RU2003123491/15A patent/RU2003123491A/ru not_active Application Discontinuation
- 2001-12-31 CA CA002435484A patent/CA2435484A1/fr not_active Abandoned
- 2001-12-31 PT PT01990621T patent/PT1349578E/pt unknown
- 2001-12-31 EP EP01990621A patent/EP1349578B1/de not_active Expired - Lifetime
- 2001-12-31 WO PCT/FR2001/004235 patent/WO2002053090A2/fr not_active Ceased
- 2001-12-31 DK DK01990621T patent/DK1349578T3/da active
- 2001-12-31 AT AT01990621T patent/ATE333901T1/de not_active IP Right Cessation
- 2001-12-31 JP JP2002554041A patent/JP4477301B2/ja not_active Expired - Lifetime
- 2001-12-31 NZ NZ527206A patent/NZ527206A/en unknown
- 2001-12-31 US US10/465,997 patent/US7265156B2/en not_active Expired - Fee Related
- 2001-12-31 ES ES01990621T patent/ES2271103T3/es not_active Expired - Lifetime
- 2001-12-31 DE DE60121804T patent/DE60121804T2/de not_active Expired - Lifetime
-
2002
- 2002-09-26 ZA ZA200207761A patent/ZA200207761B/en unknown
-
2006
- 2006-10-25 CY CY20061101542T patent/CY1105736T1/el unknown
-
2007
- 2007-07-20 US US11/878,080 patent/US20070265349A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK1349578T3 (da) | 2006-11-27 |
| EP1349578B1 (de) | 2006-07-26 |
| WO2002053090A3 (fr) | 2003-02-20 |
| PT1349578E (pt) | 2006-12-29 |
| US20040097399A1 (en) | 2004-05-20 |
| ES2271103T3 (es) | 2007-04-16 |
| CY1105736T1 (el) | 2010-12-22 |
| RU2003123491A (ru) | 2005-01-10 |
| JP4477301B2 (ja) | 2010-06-09 |
| ATE333901T1 (de) | 2006-08-15 |
| CA2435484A1 (fr) | 2002-07-11 |
| JP2004517105A (ja) | 2004-06-10 |
| FR2818906A1 (fr) | 2002-07-05 |
| ZA200207761B (en) | 2004-05-28 |
| DE60121804T2 (de) | 2007-08-23 |
| US20070265349A1 (en) | 2007-11-15 |
| FR2818906B1 (fr) | 2004-04-02 |
| US7265156B2 (en) | 2007-09-04 |
| NZ527206A (en) | 2006-12-22 |
| EP1349578A2 (de) | 2003-10-08 |
| WO2002053090A2 (fr) | 2002-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60121804D1 (de) | Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin | |
| SE0001899D0 (sv) | New compounds | |
| SE0002102D0 (sv) | Chemical compound | |
| EA200501268A1 (ru) | Ингибирующие вич 1,2,4-триазины | |
| EA200300776A1 (ru) | Производные фенэтаноламина для лечения респираторных заболеваний | |
| ATE469136T1 (de) | Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1 | |
| CY1111543T1 (el) | Νεες ενωσεις | |
| SE9904505D0 (sv) | Novel compounds | |
| BRPI0417717A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| EA200400432A1 (ru) | Производные мочевины | |
| EA200300323A1 (ru) | ПРОИЗВОДНЫЕ ГУАНИДИНОБЕНЗАМИДА (ВАРИАНТЫ), КОМПОЗИЦИЯ (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ ОПОСРЕДОВАННОГО mc4-r ЗАБОЛЕВАНИЯ (ВАРИАНТЫ) | |
| ECSP045081A (es) | Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados | |
| MX2007006397A (es) | Derivados de tetrahidropirano. | |
| MY134892A (en) | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use | |
| SE0102438D0 (sv) | New compounds | |
| ECSP044992A (es) | Inhibidores de la alquín-aril fosfodiesterasa-4 | |
| YU87202A (sh) | Derivati arilmetilamina koji se koriste kao inhibitori triptaze | |
| DE50202504D1 (de) | Neue 4-aminofuropyrimidine und ihre verwendung | |
| ATE499939T1 (de) | Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend | |
| PE20030061A1 (es) | 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4 | |
| IL159993A0 (en) | Platinum complexes and their use in cancer treatment | |
| MY134026A (en) | ?-carboline derivatives and its pharmaceutical use against depression and anxiety | |
| ATE400563T1 (de) | Neue neurokinin-antagonisten zum gebrauch als arzneimittel | |
| SE0102057D0 (sv) | New Salts I | |
| SE0101978D0 (sv) | New compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: INOPHARM, MAROMME, FR |